HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Predictive role of RRM1 and BRCA1 mRNA expression on the clinical outcome of advanced non-small cell lung cancer.

Abstract
This study aimed to evaluate the association between RRM1 and BRCA1 expressions and the therapeutic efficacy of platinum-based chemotherapy in non-small cell lung cancer patients in terms of their response and prognosis. In total, 377 patients agreed to participate in our study, and all of them received platinum-based combination chemotherapy between January 2008 and January 2009. The relative cDNA quantitation for RRM1 and BRCA1 was conducted using a fluorescence-based, real-time detection method, using β-actin as a reference gene. The average age of the 377 patients was 64.6 years (range: 25.5-86.4 years), including 269 men and 108 women. Patients with high RRM1 expression benefited more from a platinum-containing regimen, and patients with high BRCA1 expression showed a high response rate to a platinum-containing regimen and reduced disease progression. Patients with high RRM1 expression were associated with a longer progression-free survival (PFS) and overall survival (OS) than those with low expression, and the hazard ratios (HRs) (95% confidence interval (CI)) were 0.67 (0.32-0.91) and 0.54 (0.30-0.95), respectively. Patients with high BRCA1 expression showed longer PFS and OS compared to those with low expression, and the HRs (95%CI) were 0.54 (0.30-0.95) and 0.62 (0.32-0.93), respectively. These results could be used in personalized chemotherapy decisions and to increase the response rate and prolonged survival, and could encourage exploration of the predictive value of other genes.
AuthorsJ G Liang, Z Y Jin, X D Gao, M R Te, L H Ge, C L Wang
JournalGenetics and molecular research : GMR (Genet Mol Res) Vol. 13 Issue 3 Pg. 5292-8 (Jul 24 2014) ISSN: 1676-5680 [Electronic] Brazil
PMID25078585 (Publication Type: Journal Article)
Chemical References
  • BRCA1 Protein
  • BRCA1 protein, human
  • Biomarkers, Pharmacological
  • RNA, Messenger
  • Tumor Suppressor Proteins
  • Deoxycytidine
  • Vinblastine
  • RRM1 protein, human
  • Ribonucleoside Diphosphate Reductase
  • Paclitaxel
  • Cisplatin
  • Vinorelbine
  • Gemcitabine
Topics
  • Adenocarcinoma (drug therapy, genetics, mortality, pathology)
  • Adult
  • Aged
  • Aged, 80 and over
  • Antineoplastic Combined Chemotherapy Protocols
  • BRCA1 Protein (genetics, metabolism)
  • Biomarkers, Pharmacological (metabolism)
  • Carcinoma, Non-Small-Cell Lung (drug therapy, genetics, mortality, pathology)
  • Cisplatin (administration & dosage)
  • Deoxycytidine (administration & dosage, analogs & derivatives)
  • Female
  • Gene Expression
  • Humans
  • Lung Neoplasms (drug therapy, genetics, mortality, pathology)
  • Male
  • Middle Aged
  • Neoplasm Staging
  • Paclitaxel (administration & dosage)
  • RNA, Messenger (genetics, metabolism)
  • Ribonucleoside Diphosphate Reductase
  • Survival Analysis
  • Treatment Outcome
  • Tumor Suppressor Proteins (genetics, metabolism)
  • Vinblastine (administration & dosage, analogs & derivatives)
  • Vinorelbine
  • Gemcitabine

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: